Angel News

Angel News

Back to Homepage

4th June 2018

TxCell names Lonza as its CAR-Treg cellular product manufacturer


TxCell SA, a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, and Lonza Pharma & Biotech, one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets, has announced entering into a Master Service Agreement for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation. 



Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:




Enter the characters in the image shown:

Back to Homepage